Bristol-Myers Squibb stock steadies as CAR-T trial pause meets strong Q2 2026 figures
Published on 09/04/2026 at 17:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock (ISIN US1078421011) is trading around 67.5 USD on the New York Stock Exchange as of September 3, 2026, keeping the shares in the upper-60 USD range after a clear recovery from the low-50 USD levels seen at the start of 2026, according to recent market data compiled by MarketBeat.
CAR-T trial pause shapes early September sentiment
A central catalyst for Bristol-Myers Squibb in early September 2026 is the company’s decision to pause multiple clinical trials evaluating CAR-T cell therapies such as zolacabtagene autoleucel (Zola-cel) in autoimmune diseases after safety signals emerged, as reported by specialist pharma media summarizing Wall Street Journal coverage and regulatory communications.
According to a recent overview of major pharma and biotech stories, Bristol-Myers Squibb voluntarily paused enrollment in its autoimmune trials of Zola-cel after detecting transient and reversible inflammatory events during routine safety surveillance, opting for a cautious approach while further safety analyses are carried out.
Q2 2026 results provide fundamental support
Despite the CAR-T trial pause, Bristol-Myers Squibb’s latest financial figures give investors a solid fundamental backdrop. In Q2 2026, the company reported revenue of about 12.97 billion USD, which marked a clear increase versus the comparable period a year earlier and came in above market expectations according to data compiled by financial portals referencing the company’s July 30, 2026 quarterly update.
On the earnings side, Bristol-Myers Squibb generated adjusted EPS of approximately 2.04 USD in Q2 2026, exceeding consensus forecasts for the quarter and reflecting operating leverage from its core cardiovascular and oncology franchises.
The company coupled its Q2 2026 beat with a raised full year 2026 guidance for both revenue and adjusted EPS, signaling confidence that growth in key products such as Eliquis and newer medicines including Reblozyl, Camzyos and Breyanzi can offset patent expiries and competitive pressures in other parts of the portfolio.
Stock performance and valuation in 2026
From a market perspective, Bristol-Myers Squibb stock has staged a notable recovery in 2026. Market data compiled by MarketBeat indicate that the shares traded at roughly 53.93 USD at the beginning of 2026 and have since climbed to around 67.53 USD as of September 3, 2026, representing a gain of about 25.3 percent year to date and positioning the stock closer to the upper end of its recent trading range.
This year to date performance is accompanied by a higher market capitalization. One recent quote snapshot based on New York Stock Exchange trading shows Bristol-Myers Squibb’s equity value at approximately 136.7 billion USD as of September 2, 2026, underlining how the company’s pipeline prospects and Q2 2026 guidance have been capitalized by the market.
In the broader context of large pharmaceutical peers, this 25.3 percent year to date rise suggests that investors have been willing to re-rate the shares on the back of improved earnings visibility, even as regulatory and safety scrutiny of advanced therapies such as CAR-T remains intense.
Focus on CAR-T safety and autoimmune opportunity
The decision to pause autoimmune CAR-T trials touches a strategically important area for Bristol-Myers Squibb. Zolacabtagene autoleucel (Zola-cel) represents one of the company’s key cell therapy candidates aimed at autoimmune conditions, building on experience in hematologic malignancies and seeking to expand into high unmet need indications.
Reports citing regulatory briefings indicate that Bristol-Myers Squibb informed regulators, researchers and patient advocacy groups in early June 2026 that it was pausing these trials after observing life threatening side effects in some patients, a move that underscores the complexity of translating CAR-T technology from oncology into chronic autoimmune diseases.
For investors, the key question is whether the pause reflects manageable safety issues that can be addressed through protocol changes and tighter monitoring or whether it points to more fundamental limitations for this approach in autoimmune indications. The company’s decision to frame the inflammatory events as transient and reversible in more recent pharma trade summaries suggests that work is ongoing to find a viable path forward.
More on Bristol-Myers Squibb stock and fundamentals
Read additional coverage and data on Bristol-Myers Squibb shares, including past earnings reports and pipeline updates, via the issuer overview and investor relations materials.
Eliquis and specialty portfolio as revenue drivers
In its Q2 2026 update, Bristol-Myers Squibb highlighted that anticoagulant Eliquis continues to be a major revenue contributor, helping to anchor the company’s cardiovascular franchise. Growth in Eliquis volumes and continued strong demand in stroke prevention added to revenue resilience in the quarter, according to financial portal summaries of the July 30, 2026 results.
Beyond Eliquis, newer therapies such as Reblozyl for anemia, Camzyos for hypertrophic cardiomyopathy and cell therapy Breyanzi for certain lymphoma indications have been cited as important growth vectors. These products contributed to the mid single digit to double digit percentage revenue increases in their respective franchises in Q2 2026 compared with the prior year period, strengthening the case for Bristol-Myers Squibb’s transition toward a more diversified mix of innovative therapies.
For long term shareholders, the Q2 2026 figures suggest that the company’s strategy of investing heavily in specialty medicines and advanced modalities is translating into measurable financial results, even as parts of the legacy portfolio face price pressure and competition.
Stock near upper end of recent trading range
From a technical perspective based on recent quote snapshots, Bristol-Myers Squibb stock’s move from around 53.93 USD at the start of 2026 to approximately 67.53 USD on September 3, 2026 places the shares closer to the upper end of their recent 2026 trading corridor, with the year to date rise of about 25.3 percent underlining improved sentiment among market participants.
Some recent analyses characterize the stock as still attractively valued on forward earnings metrics despite this rally, pointing to a combination of solid cash flows, a growing specialty pipeline and shareholder returns via dividends and buybacks as supporting factors for the current valuation level.
In the broader large pharma peer group, where many names have seen more moderate single digit to low double digit percentage advances in 2026, Bristol-Myers Squibb’s approximately 25.3 percent year to date performance stands out as evidence that investors are rewarding companies that pair visible earnings growth with a robust pipeline in high need areas such as cardiovascular and oncology.
Representative product focus: Eliquis
Eliquis, co developed with a large European pharmaceutical partner, remains one of Bristol-Myers Squibb’s flagship products. The oral anticoagulant is widely prescribed for stroke prevention in patients with non valvular atrial fibrillation and for the treatment and prevention of deep vein thrombosis and pulmonary embolism.
In Q2 2026, revenue from Eliquis contributed a substantial share of Bristol-Myers Squibb’s 12.97 billion USD total sales, with demand trends indicating ongoing uptake in both the United States and international markets. For investors, the performance of Eliquis is central to assessing the stability of the company’s cash flow profile over the medium term.
Stock price and investor perspective
As of September 3, 2026, Bristol-Myers Squibb stock is quoted at approximately 67.53 USD on the New York Stock Exchange, giving the company a market capitalization in the mid 130 billion USD range and reflecting a year to date performance of about 25.3 percent from an early 2026 level of 53.93 USD according to MarketBeat data. For investors, the interplay between the CAR-T trial pause and the strong Q2 2026 fundamentals will remain a key theme in assessing the risk reward profile of Bristol-Myers Squibb shares.
Bristol-Myers Squibb at a glance
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- Ticker: BMY
- Trading venue: New York Stock Exchange
- Price (as of September 3, 2026): 67.53 USD
- Market capitalization: 136.7 billion USD (as of September 2, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S and P 500
